Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022
July 29, 2022 at 07:00 am
Share
Shin Nippon Biomedical Laboratories, Ltd. revised earnings guidance for the six months ending September 30, 2022 and fiscal year ending March 31, 2022. For the six months, the company revised net sales to JPY 10,570 million from JPY 9,500 of previous guidance and operating profit is revised to JPY 2,510 million from JPY 2,450 million from previous guidance. The profit attributable to owners of parent is revised to JPY 3,310 million from JPY 2,050 of previous guidance and profit per share is revised to JPY 79.50 from JPY 49.24 of previous guidance.
For the six months, the company revised net sales to JPY 22,830 million from JPY 19,600 of previous guidance and operating profit is revised to JPY 5,210 million from JPY 5,000 million from previous guidance. The profit attributable to owners of parent is revised to JPY 5,590 million from JPY 4,300 of previous guidance and profit per share is revised to JPY 134.27 from JPY 103.28 of previous guidance.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
